Pluristem Therapeutics Inc.(NASDAQ:PSTI) stock gained 6.83% to $4.69. The company last week announced that the Company's Placental eXpanded (PLX) cells were successfully administered to a third patient in Hadassah Medical Center; thus, a series of three life saving compassionate use treatments were completed. The outcome of those treatments potentially suggests that the Company's PLX cells may have significant potential to treat a range of indications of bone marrow diseases.
Will PSTI Continue To Move Higher? Find Out Here
National Bank of Greece (ADR) (NYSE:NBG) shares jumped 8.13% to $2.14. The 52 week trading range for the company is $1.12 - $4.75. The shares of the company plunged 52% in the last one year. The company is a Greece-based financial institution. It offers a range of integrated financial services, including corporate and investment banking, retail banking (including mortgage lending), leasing, stock brokerage, asset management and venture capital, insurance, real estate and consulting services.
Inovio Pharmaceuticals, Inc.(NYSEAMEX:INO) shares climbed 7.39% to $0.610. The company announced that the interim analysis of its SynCon universal H1N1 influenza vaccine showed that it generated protective HAI titers against some of the most prevalent strains of H1N1 influenza from the past 100 years in a phase I clinical trial.
ReneSola Ltd. (ADR)(NYSE:SOL) shares increased 6.57% to $1.46. The company, on August 27, announced that it has agreed to sell 4.6 megawatts (MW) of its high-quality, high-efficiency 255 watt (W) poly modules to Solar Planet Power Inc. (Solar Planet). Under the terms of the agreement, ReneSola will ship a total of 4.6 MW of its high-efficiency 255 W poly modules to Solar Planet in the third quarter of 2012. Solar Planet intends to order up to 15 MW of additional solar modules within six months following the initial delivery.
How Should Investors Trade SOL Now? Find Out Here
Neuralstem, Inc.(NYSEAMEX:CUR) stock gained 9.77% to $0.730. The company announced that it has granted the first licenses for use of its Spinal Cord Delivery Platform and Floating Cannula, for delivering therapeutic agents to the spinal cord, to Salt Lake City-based Q Therapeutics. This platform and cannula have been in use since 2010, in the recently completed Phase I ALS trial delivering Neuralstem's NSI-566 neural stem cells into the spinal cords of patients with amyotrophic lateral sclerosis.